Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck
Phase 2
Recruiting
- Conditions
- Squamous Cell Carcinoma Of The Head And Neck
- Interventions
- Drug: PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin
- Registration Number
- NCT03830385
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
The purpose of this single arm, phase Ⅱ clinical trail is to determine the safety and efficacy of paclitaxel (albumin bound),bleomycin and cisplatin or carboplatin in the treatment of recurrent Or metastatic squamous cell carcinoma of the head and neck
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
- biopsy proved squamous cell carcinoma of the head and neck;
- stage IVc according to Union for International Cancer Control (UICC) edition VIII, or recurrent disease after chemotherapy and/or radiotherapy;
- 18 years or older; without other malignancy;
- proper functioning of the major organs.
Exclusion Criteria
- allergic to paclitaxel (albumin bound) or bleomycin or cisplatin or carboplatin ;
- female within gestation period or lactation;
- patients received drug of other clinical trial within 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Paclitaxel (Albumin Bound),Bleomycin and Cisplatin or PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin -
- Primary Outcome Measures
Name Time Method overall survival 5 years overall survival
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
🇨🇳Guangzhou, Guangdong, China